Epidemiology and Management of Metastatic Breast Cancer
NCT ID: NCT01711502
Last Updated: 2014-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
128 participants
OBSERVATIONAL
2013-01-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)
NCT01277133
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
NCT01215123
Clinico-biological Data Collection Study of Metastatic Breast Cancer
NCT03958136
Metabolomics Explores Biomarkers for Metastatic Breast Cancer
NCT04302415
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
NCT04158258
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Female patients diagosed with metastatic breast cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis between 1st July 2010 - 30th June 2011
* Female patient managed for her disease at the same setting where final diagnosis of MBC was performed
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dediu Mrcea, SENIOR PHYSICIAN
Role: PRINCIPAL_INVESTIGATOR
Bucharest Institute of Oncology
Alexandru Eniu, SENIOR PHYSICIAN
Role: PRINCIPAL_INVESTIGATOR
Cluj Institute of Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Doina Coste Gherasim
Baia Mare, , Romania
Daniel Ciurescu
Brasov, , Romania
Dana Lucia Stanculeanu
Bucharest, , Romania
Dragos Median
Bucharest, , Romania
Mircea Dediu
Bucharest, , Romania
Rodica Tudor
Bucharest, , Romania
Alexandru Eniu
Cluj-Napoca, , Romania
Gabriela Morar Bolba
Cluj-Napoca, , Romania
Bena Sandra
Craiova, , Romania
Nelly Cherciu
Craiova, , Romania
Diana Petroiu
Iași, , Romania
Simona Angelescu
Târgovişte, , Romania
Cristina Oprean
Timișoara, , Romania
Stefan Curescu
Timișoara, , Romania
Cristina Elen Pirau
Vaslui, , Romania
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-ORO-XXX-2012/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.